See today's BioWorld
To read the full story, subscribe or sign in.

FDA authorizes first NGS test to detect critical HIV-1 drug resistance mutations

Nov. 7, 2019
By Meg Bryant
Singapore-based Vela Diagnostics Holding Pte. Ltd. has received U.S. FDA authorization via the de novo approval pathway for an in vitro diagnostic test to detect HIV-1 genomic drug resistance mutations (DRMs).
BioWorld Medical devices and technologies